0001209191-18-002547.txt : 20180105
0001209191-18-002547.hdr.sgml : 20180105
20180105183024
ACCESSION NUMBER: 0001209191-18-002547
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180104
FILED AS OF DATE: 20180105
DATE AS OF CHANGE: 20180105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yurasov Sergey
CENTRAL INDEX KEY: 0001686295
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36561
FILM NUMBER: 18514484
MAIL ADDRESS:
STREET 1: C/O IMMUNE DESIGN CORP.
STREET 2: 1616 EASTLAKE AVE. E., SUITE 310
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Immune Design Corp.
CENTRAL INDEX KEY: 0001437786
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262007174
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1616 EASTLAKE AVE. E
STREET 2: SUITE 310
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: (206) 682-0645
MAIL ADDRESS:
STREET 1: 1616 EASTLAKE AVE. E
STREET 2: SUITE 310
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: VACCSYS INC
DATE OF NAME CHANGE: 20080617
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-01-04
0
0001437786
Immune Design Corp.
IMDZ
0001686295
Yurasov Sergey
C/O IMMUNE DESIGN CORP.
1616 EASTLAKE AVE. E., SUITE 310
SEATTLE
WA
98102
0
1
0
0
Sr. VP, Clinic. Devel. & CMO
Common Stock
2018-01-04
4
A
0
22000
0.00
A
28000
D
Common Stock
2018-01-04
4
S
0
675
4.1725
D
27325
D
Stock Option (right to buy)
4.05
2018-01-04
4
A
0
110000
0.00
A
2028-01-04
Common Stock
110000
110000
D
Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock.
Restricted stock units shall vest in a series of three equal consecutive annual installments beginning on January 4, 2019, subject to the Reporting Person's continuous service through each such date.
One quarter of the shares underlying the option will vest on January 4, 2019, and the remainder of the shares underlying the option will vest at a rate of 1/24th per month thereafter, subject to the Reporting Person's continuous service through each such date.
/s/ Stephen R. Brady, Attorney-In-Fact
2018-01-05